New NICE drug recommendation for RRMS

The National Institute for Health and Care Excellence (NICE) in the UK has issued a positive recommendation for the use of ublituximab (BRIUMVI®) in the treatment of relapsing remitting multiple sclerosis (MS).

Ublituximab is an antibody that works in a similar was to the drug Ocrevus (ocrelizumab) by binding to the surface of B cells in the immune systems and reducing their numbers. It’s these B cells which attack heathy tissue when you have MS.

The drug was developed by TG Therapeutics, and is the first and only anti-CD20 monoclonal antibody that is approved in the US and the EU for RRMS that can be administered just twice a year via a one-hour infusion.

By targeting and removing B cells, ublituximab reduces the chance of a relapse, relieves symptoms and slows disease progression.